Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-04-02 17:55:13 ET · period of report 2026-04-01 · accession 0001283303-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-02 17:55 | 2026-04-01 | TVTX | REED ELIZABETH E | CLO, GC | M - OptEx | $15.46 | +10.0K | 115.2K | +10% | +$154.6K |
| DT | 2026-04-02 17:55 | 2026-04-01 | TVTX | REED ELIZABETH E | CLO, GC | S - Sale+OE | $30.00 | -10.0K | 105.2K | -9% | -$300.0K |
| DT | 2026-04-02 17:55 | 2026-04-01 | TVTX | REED ELIZABETH E | CLO, GC | M - OptEx | $0.00 | -10.0K | 45.0K | -18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-01 | M | A | 10,000 | $15.46 | 115,211 | D | — | — | |
| 2 | Common | Common Stock | 2026-04-01 | S | D | 10,000 | $30.00 | 105,211 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020. |
| 3 | Derivative | Employee stock option (right to buy) | 2026-04-01 | M | D | 10,000 | $0.00 | 45,000 | D | $15.46 · — to 2030-01-31 | 10,000 Common Stock | (F2) The stock option is fully vested and exercisable. |